Idorsia Pharmaceuticals Ltd: The Journal of Neurosurgery rep

Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety

Related Keywords

Japan , Togo , Allschwil , Switzerland General , Switzerland , Tohoku , Japan General , Japanese , Swiss , Clin Neurosci , Andrewc Weiss , Satoshi Tanaka , Teiji Tominaga , Department Of Neurosurgery , Idorsia Ltd , Tohoku University Graduate School Of Medicine , Head Of Investor Relations Corporate Communications , Idorsia Pharmaceuticals Ltd , Idorsia Pharmaceuticals Japan , Swiss Exchange , Tohoku University Graduate School , Cerebral Vasospasm , Clipping Surgery , Aneurysmal Subarachnoid Hemorrhage , Pharmacol Exp , Lancet Neurology , Overcome Neurological Ischemia , Pharmaceuticals Japan , Vice President , Investor Relations , Pharmaceuticals Ltd , Idorsia , Pharmaceuticals , Journal , Neurosurgery , Reports , Impact , Clazosentan , Scerebral , Vasospasm , Elated , Morbidity , Cause , Ortality , After , Neurysmal , Ubarachnoid , Hemorrhage ,